Subscribe To

Price Alert Latest News Economic Calendar News

AZN / AstraZeneca PLC (AZN) Q2 2023 Earnings Call Transcript

AstraZeneca PLC (NASDAQ:AZN ) Q2 2023 Earnings Conference Call July 28, 2023 6:45 AM ET Company Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Chief Executive Officer Aradhana Sarin - Chief Financial Officer David Fredrickson - Executive Vice-President, Oncology Business Unit Susan Galbraith - Executive Vice President, Oncology Research & Development Ruud Dobber - EVP of BioPharmaceuticals Business Unit Mene Pangalos - Executive Vice-President, BioPharmaceuticals R&D Marc Dunoyer - Chief Executive Officer, Alexion Leon Wang - Executive Vice-President, International & China President Conference Call Participants Sachin Jain - Bank of America Tim Anderson - Bernstein Andrew Baum - Citi Mark Purcell - Morgan Stanley Gonzalo Artiach - ABG Richard Parkes - Exane Christopher Uhde - SEB James Gordon - JPMorgan Emily Field - Barclays Victor Sanders - Nordea Steve Scala - Cowen Simon Baker - Redburn Seamus Fernandez - Guggenheim Matt Weston - Credit Suisse Eric Le Berrigaud - Stifel Peter Welford - Jefferies Luisa Hector - Berenberg Operator Good morning to those joining from the UK and the US. Good afternoon to those in Central Europe, and good evening to those listening in Asia. Read More

Demo Live Account See Partner Details

Content Topics

Astrazeneca

AZN

2023

Earnings

Call

Transcript

Stock

Posted: Jul 28 2023, 13:34

Author Name: Seeking Alpha

AZN News

By Proactive Investors
November 1, 2023

AstraZeneca inks gene editing deal that could end up costing it $2.5bn

AstraZeneca PLC (LSE:AZN) has entered into a partnership and investment deal with French gene editing specialist biotech firm Cellectis (NASDAQ:CLLS)

By Reuters
November 1, 2023

AstraZeneca signs drug development deal with biotech Cellectis

AstraZeneca said on Wednesday it had entered into a collaboration and investment agreement with clinical-stage biotechnology company Cellectis to spee

By Zacks Investment Research
October 31, 2023

Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know

In the most recent trading session, Astrazeneca (AZN) closed at $63.23, indicating a +0.46% shift from the previous trading day.

By Zacks Investment Research
October 30, 2023

Is Trending Stock AstraZeneca PLC (AZN) a Buy Now?

Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact th

By The Motley Fool
October 28, 2023

3 No-Brainer Stocks to Buy for Under $100 Right Now

AstraZeneca's slump presents a great buying opportunity. BioNTech's future prospects go well beyond COVID-19.

By Market Watch
October 25, 2023

These healthcare stocks should come to life as boomers live their golden years

Baby boomers: Love ‘em or hate ‘em, the juggernaut generation changes every aspect of life it steamrolls through. Now it's doing the same to healt

By Proactive Investors
October 24, 2023

Barclays and AstraZeneca up staff pay as Real Living Wage increases

Employers which pay staff the Real Living Wage (RLW) will have to find an extra 10% after it was increased to £12 in the UK and £13.10 in London on

By Market Watch
October 24, 2023

AstraZeneca said U.S. FDA has accepted for review its Flumist self-administered flu vaccine

AstraZeneca PLC AZN, -1.22% AZN, +1.45% said Tuesday the U.S. Food and Drug Administration has accepted its application for approval of a self-adminis

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.